G
GenEdit
Developing innovative therapies through targeted delivery of genetic medicines
About GenEdit
GenEdit is a pioneering biotechnology company focused on revolutionizing gene therapy and gene editing through its proprietary nanoparticle delivery technology. The company operates in the biotechnology and pharmaceutical markets, primarily serving clients in the medical and healthcare sectors who are in need of advanced gene therapy solutions. GenEdit's core technology involves engineering individual components of the CRISPR system to create a comprehensive delivery system for CRISPR-based therapeutics. This approach includes both proprietary engineering and novel nanoparticles, which enable safer and more efficient delivery options for gene knockout therapies.
Read full description
Founded in 2016 with roots at the University of California, Berkeley, GenEdit has developed a proprietary polymer nanoparticle library. The company has established initial proof of concept by successfully delivering CRISPR Cas9 and gene editors to target tissues, leading to publications in key journals such as Nature Biomedical Engineering and Nature Communications. GenEdit's business model revolves around leveraging its proprietary technology to develop and commercialize gene therapies, generating revenue through partnerships, licensing agreements, and direct sales of its therapeutic solutions.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Brisbane, United States
- Employees
- 64
- Open positions
- 2
- Dealroom signal
- 84.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Synthetic Biology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning GenEdit.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Feb 2026 | $60M | $240M | Undisclosed | ↗ |
| SERIES AOther financing | Jan 2024 | $24M | $96M | Korea Investment Partners · K2 Investment Partners · IMM Investment · DAYLI Partners | ↗ |
Growth signals
Latest recorded traffic for GenEdit is 5.8K monthly website visits, up 65.7% over the last three months. GenEdit's team grew 10.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A19 investors entered at this stage
Eli Lilly- DNDaol Investment (Formerly KTB Network)
KB Investment
IMM Investment
DAYLI Partners
Company K Partners
Korea Investment Partners- TMTimefolio Asset Management
K2 Investment Partners
Terra VC
Kimco Realty
ACVC Ventures
Woori Venture Partners
Mirae Asset Venture Investment
Korea Development Bank
Huons
Dong-A ST- PPPathway Partners
- LILoftyrock Investment
Other known investors1 additional known investor
University of California, Berkeley
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GenEdit on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GenEdit’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.